Fig. 4.

Comparison of the effect of an IDO1-specific ASO and an IDO1-specific small molecule inhibitor on kynurenine production in human cancer cells. EFO-21 cells were treated with the IDO1-specific ASO A06030H and Epacadostat at different concentrations. In the case of ASO, cells were treated for 3 days before adding tryptophan supplemented medium for 24 h. In the case of Epacadostat, cells were treated with the small molecule during incubation in tryptophan supplemented medium for 24 h. Kynurenine levels were measured by ELISA 24 h after the start of incubation in tryptophan supplemented medium. The mean of four replicates from two independent experiments is shown. Significant differences compared to mock-treated cells were determined using one-way ANOVA followed by Dunnett’s multiple comparison test